Jessica K W Tsang1, Susanne A Wolf2, Inga M Pompoes2, Antonia M Joussen2, Wai Ching Lam1, Di Yang3, Amy C Y Lo1. 1. Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 2. Department of Ophthalmology, Charité-University Medicine Berlin, 10117 Berlin, Germany. 3. Department of Ophthalmology, First Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming 650500, China.
Abstract
Retinopathy of prematurity (ROP), the most common cause of childhood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function; however, it is disrupted when pathological angiogenesis is induced in ROP patients. Under hypoxia, inadequate oxygen and energy supply lead to oxidative stress and stimulate neovasculature formation as well as affecting the function of photoreceptors. In order to meet the metabolic needs in the developing retina, protection against abnormal vascular formation is one way to manage ROP. Although current treatments provide beneficial effects in reducing the severity of ROP, these invasive therapies may also induce life-long consequences such as systemic structural and functional complications as well as neurodevelopment disruption in the developing infants. Nutritional supplements for the newborns are a novel concept for restoring energy supply by protecting the retinal vasculature and may lead to better ROP management. Nutraceuticals are provided in a non-invasive manner without the developmental side effects associated with current treatments. These nutraceuticals have been investigated through various in vitro and in vivo methods and are indicated to protect retinal vasculature. Here, we reviewed and discussed how the use of these nutraceuticals may be beneficial in ROP prevention and management.
Retinopathy of prematurity (ROP), the most common cause of childhn class="Chemical">ood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function; however, it is disrupted when pathological angiogenesis is induced in ROP patients. Under hypoxia, inadequate oxygen and energy supply lead to oxidative stress and stimulate neovasculature formation as well as affecting the function of photoreceptors. In order to meet the metabolic needs in the developing retina, protection against abnormal vascular formation is one way to manage ROP. Although current treatments provide beneficial effects in reducing the severity of ROP, these invasive therapies may also induce life-long consequences such as systemic structural and functional complications as well as neurodevelopment disruption in the developing infants. Nutritional supplements for the newborns are a novel concept for restoring energy supply by protecting the retinal vasculature and may lead to better ROP management. Nutraceuticals are provided in a non-invasive manner without the developmental side effects associated with current treatments. These nutraceuticals have been investigated through various in vitro and in vivo methods and are indicated to protect retinal vasculature. Here, we reviewed and discussed how the use of these nutraceuticals may be beneficial in ROP prevention and management.
Authors: Abhay Lodha; Mary Seshia; Douglas D McMillan; Keith Barrington; Junmin Yang; Shoo K Lee; Prakesh S Shah Journal: JAMA Pediatr Date: 2015-01 Impact factor: 16.193
Authors: J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild Journal: J Neurosci Date: 2001-05-15 Impact factor: 6.167
Authors: María A Martínez-Castellanos; Shulamit Schwartz; Myriam L Hernández-Rojas; Veronica A Kon-Jara; Gerardo García-Aguirre; José L Guerrero-Naranjo; R V Paul Chan; Hugo Quiroz-Mercado Journal: Retina Date: 2013-02 Impact factor: 4.256
Authors: Claire Billerey-Larmonier; Jennifer K Uno; Nicolas Larmonier; Anna J Midura; Barbara Timmermann; Fayez K Ghishan; Pawel R Kiela Journal: Inflamm Bowel Dis Date: 2008-06 Impact factor: 5.325
Authors: Lorena Olivares-González; David Salom; Emilio González-García; David Hervás; Natalia Mejía-Chiqui; Mar Melero; Sheyla Velasco; Bianca Tabita Muresan; Isabel Campillo; Nieves Vila-Clérigues; Eduardo López-Briz; Juan Francisco Merino-Torres; José María Millán; José Miguel Soriano Del Castillo; Regina Rodrigo Journal: Front Nutr Date: 2022-03-21
Authors: Lorena Olivares-González; Sheyla Velasco; Isabel Campillo; David Salom; Emilio González-García; José Miguel Soriano Del Castillo; Regina Rodrigo Journal: Antioxidants (Basel) Date: 2021-06-26